Vaxcyte Announces Webcast to Present Study Results
Vaxcyte, Inc. (NASDAQ: PCVX), a leader in vaccine innovation, has exciting news. The company has scheduled a webcast and conference call to unveil the topline results of its Phase 1/2 study on VAX-31, a 31-valent pneumococcal conjugate vaccine, specifically aimed at adults aged 50 and older. This event is set for 8:00 a.m. Eastern Time.
Understanding VAX-31
VAX-31 stands out as a candidate designed to combat invasive pneumococcal disease (IPD). This Phase 1/2 study focuses on its safety, tolerability, and immunogenicity among healthy adults in the target age group. The objective is clear: to establish VAX-31 as a formidable option for preventing infections resulting from pneumococcal bacteria.
How to Join the Webcast
Participants interested in tuning into the conference call can dial 800-225-9448 for domestic calls or 203-518-9708 for international access. Be sure to reference conference ID PCVX0903 during the call. Additionally, a live webcast will be hosted on Vaxcyte's investor relations webpage, offering a convenient option for those who prefer online attendance.
Archiving the Replay
For those who cannot attend the live event, a replay will be available on the Vaxcyte website for 30 days following the presentation, ensuring that critical information is accessible to all interested parties.
The Vaxcyte Vision
At the heart of Vaxcyte’s mission is the advancement of high-fidelity vaccines to address bacterial diseases that impact global health. The company is not just focusing on VAX-31; it's also working on VAX-24, a 24-valent vaccine that's ready for Phase 3 trials. This innovative approach combines a broad-range of coverage against several serotypes responsible for significant IPD, enhancing protection for both children and adults.
Innovative Vaccine Development
Vaxcyte is at the forefront of vaccine technology, using modern synthetic techniques like the XpressCF™ cell-free protein synthesis platform. This method, which is exclusively licensed from Sutro Biopharma, allows for the efficient production of complex proteins and antigens. This technological edge is crucial for developing efficient, high-fidelity vaccines that can enhance immunological benefits.
Additional Vaccine Candidates
In addition to VAX-31 and VAX-24, Vaxcyte is developing an array of vaccine candidates aimed at various bacterial infections. Notable developments include VAX-A1, targeting Group A Strep infections, VAX-PG, aimed at periodontal disease, and VAX-GI, designed to prevent Shigella. Each of these candidates represents Vaxcyte's commitment to tackling serious health issues linked to bacterial infections.
Contact Information
For inquiries, Patrick Ryan, Executive Director of Corporate Communications, is available at 415-606-5135, and media inquiries can be directed to media@vaxcyte.com. Investor relations can be reach through Jennifer Zibuda at 860-729-8902 or via email at investors@vaxcyte.com.
Frequently Asked Questions
What is VAX-31?
VAX-31 is a 31-valent pneumococcal conjugate vaccine candidate aimed at preventing invasive pneumococcal disease in adults aged 50 and older.
When is the webcast scheduled?
The webcast will take place at 8:00 a.m. Eastern Time on the day following the announcement.
How can I participate in the conference call?
Participants can join by dialing 800-225-9448 for domestic calls or 203-518-9708 for international calls, using conference ID PCVX0903.
Will a replay be available?
Yes, a replay of the webcast will be available on the Vaxcyte website for 30 days post-event.
What other vaccines is Vaxcyte developing?
In addition to VAX-31 and VAX-24, Vaxcyte is developing VAX-A1 for Group A Strep, VAX-PG for periodontal disease, and VAX-GI for Shigella prevention.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Praxis Precision Medicines to Share Key EMBOLD Study Findings
- Mar-a-Lago Profits Surge: Implications for Trump Media
- Parental Control Software Market Reaches New Heights
- AnoVault: The Future of Easy Crypto Investing
- Exploring the Future of Open Source Business Models
- Market Outlook Ahead of Key Jobs Report
- Growth of Convex Ostomy Care Bag Market Insights
- Hewlett Packard's Ongoing Pursuit of Late Executive's Estate
- Growth of U.S. Wetland Management Market Explored
- Understanding Total Voting Rights of Alliance Trust PLC
- Understanding the Impact of Emerging Markets Decline
- Analyzing the Impact of U.S. Economic Data on Bitcoin
- MasHash: The Innovative Cloud Mining Solution of 2024
- Dundee Precious Metals Completes Sale of Tsumeb Smelter
- Software Defined Data Center Market Growth Insights
- Understanding Net Asset Value of Middlefield Canadian Income PCC
- Disclosure of Interests in Keywords Studios Plc Securities
- Growth of Bike Sharing Market Expected to Hit $18.64 Billion
- Market Values of Tech Companies Decline Amid Concerns
- The Future of DexCom: Growth and Opportunities Ahead
- The Impact of Dollar Weakness on Global Economies
- Lucinda Crabtree Takes Helm as CFO of Oxford Biomedica
- REA Group Explores Acquisition of Rightmove Plc
- Exploring the Future of Bitcoin: 3 Key Factors
- Impact of Real Estate Market Assessments on Risk Assets
Recent Articles
- Data Center Physical Security Set to Surpass USD 5 Billion
- Unlocking Million-Dollar Retirement with ETFs
- Management Trading Insights: Understanding Company Actions
- Cargotec Corporation's Recent Share Repurchase Activity
- Smart Irrigation Controllers Market Growth Analysis
- Novo Resources to Showcase at Gold Coast Investor Conference
- Understanding Net Asset Values of WisdomTree ETFs
- Buffett's Investing Strategy and Berkshire's Milestone
- Woolworths Exits Endeavour Group: A Strategic Move
- Atos Faces Financial Challenges Amid Restructuring Plans
- Investing Insights: Top Semiconductor Stocks for Growth
- Sanoma Introduces Innovative Social Bond Framework
- Update on Early Redemptions for Jyske Realkredit Bonds
- OKX Launches Improved Smart Arbitrage Trading Bot
- Overview of Total Voting Rights for OSB Group PLC
- Understanding Total Voting Rights and Capital Structure
- Atos Group Financial Update and Business Projections
- Asian Markets Optimism Amid Potential U.S. Economic Growth
- Bolt's Fundraising Efforts Spark Controversy
- Maximize Your Savings: Current Account Interest Rates
- Billionaires Eyeing Bitcoin and Ethereum for Diversification
- Impact of Consumer Trends on Retail Stocks
- Abaxx Technologies Acquires PrivacyCode, Inc.
- Seamless Group Completes Merger to Go Public as CURRENC
- Biodexa Pharmaceuticals Faces Nasdaq Delisting